Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...
CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...
The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...
Effect of branched-chain amino acid metabolic interactions between HIBADH+ tumor cells and BCAT1+ macrophages on immunotherapy response in advanced NSCLC. Baseline DLCO 1.04 (0.99-1.1);p=0.1 1.04 ...
A 2% decline in FVC or DLco significantly increases the risk of death or lung transplant in IPF patients, challenging current clinical thresholds. The study suggests that smaller declines in lung ...
Please provide your email address to receive an email when new articles are posted on . All-cause mortality in COPD patients was “strongly predicted” by diffusing capacity of the lung for carbon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results